PharmaShots | Incisive News in 3 Shots

Subscribe Now

Resected

BMS Reports Update of Opdivo (nivolumab) + Yervoy (ipilimumab) in P-III CheckMate -915 Study for Patients with Resected High-Risk Melanoma and PD-L1

BMS Reports Update of Opdivo (nivolumab) + Yervoy (ipilimumab) in P-III CheckMate -915 Study for Patients with Resected High-Risk...

November 20, 2019

Merck's Keytruda (pembrolizumab) Receives EU Approval for Resected Stage III Melanoma in Adults

Merck's Keytruda (pembrolizumab) Receives EU Approval for Resected Stage III Melanoma in Adults

December 18, 2018

Contact Us

First Floor, B-66, Sector 63 Noida, Uttar Pradesh, INDIA - 201301
+91-120 428 0707
connect@pharmashots.com
Newsletter

Our Information

Follow Us